January 09, 2025

Introduction

A wholesale distributor must adhere to Good Distribution Practices (GDP) in order to guarantee that the integrity and quality of medications are preserved throughout the supply chain.
The pharmaceutical sector places a great deal of attention on good distribution processes, which guarantee the preservation of product safety and quality throughout the supply chain. The pharmaceutical industry's Good Distribution Practices (GDP) Compliance report shows a dedication to quality and good practices throughout the pharmaceutical distribution supply chain.
Because of their specific shelf life and storage requirements, managing the quality of medications during distribution is challenging. For storage and shipping, different dosage forms—such as pills, syrups, and injectable—need different environmental conditions. Extra caution is needed while storing cold chain items, which are kept between 2°C and 8°C, to avoid quality failures during testing. The goal of GDP rules is to control how manufacturers store and distribute goods to patients or their representatives.
By the time it reaches the patient, a vaccine or pill produced with good manufacturing practice (GMP) at a cutting-edge facility and then distributed through an unclean, harmful, and uncontrolled supply chain is just as dangerous to use as one produced with no GMP oversight.



Good distribution methods ensure the integrity and efficacy of the pharmaceutical supply chain by focusing on key components at every stage.

Essential elements of GDP

The integrity and effectiveness of the pharmaceutical supply chain are guaranteed by Good Distribution Practices, which include a number of essential elements, these are as below –

1. **Storage Conditions and Warehouse Management**

Efficient storage solutions are essential, necessitating secure facilities and temperature-controlled settings to shield goods from the elements and unwanted access. To preserve product quality, warehouses must follow strict regulations on temperature, humidity, and cleanliness.

2. **Transportation and Logistics**

Poor handling might reduce the effectiveness of medications; transportation plays vital role to GDP. Temperature-controlled shipping containers and real-time tracking technologies are mandatory components of logistics strategies to monitor and reduce hazards during transportation.

3. **Handling of Products and Maintenance of the Cold Chain**

When handling items that are sensitive to temperature changes, careful attention must be paid to maintaining the cold chain to avoid contamination and damage. Using certain packing materials and tools to maintain items within the necessary temperature ranges during distribution is part of this.

4. **Documentation and Record-Keeping**

In the pharmaceutical supply chain, traceability and accountability depend on accurate documentation and record-keeping. To guarantee compliance and make audits easier, this entails keeping thorough records of handling protocols, transit logs, and storage conditions.

5. **Principles of good distribution practices**

When pharmaceutical items are being distributed from manufacturers to patients, Good Distribution Practices (GDP) are essential to preserving their integrity and quality. As mandated by the product specification or marketing authorization, these procedures guarantee that medications are handled, transported, and kept consistently under the right circumstances.

Management processes

1 Organization and management
3 Quality Management System
10 Complaint handling
17 Self-Inspections
18 Measurement, Analysis and improvement
19 Digitalization
20 Risk Management
21 Sustainability – green revolution
16 Internal quality audits

Operational processes

4 Premises, Equipment, Storage Conditions and Warehouse Management
5 Transportation and Logistics
6 Shipment containers and container labelling, handling of Products and Maintenance of the Cold Chain
7 Delivery and Receipt of goods
12 Returns, Procedures for handling returned goods, rejected products

Support processes

2 Personnel / People management
8 Documentation and Record-Keeping
9 Repackaging & Relabelling
11 Recalls

13 Suspected Falsified Medicinal Products
14 Importation
15 Contract activities / Order preparation / Outsourcing process management

Risk management principles should be applied throughout the supply chain to identify, assess, and minimize risks related to product quality and distribution:

The best practices for risk management are outlined for distribution workers. They outline how companies should include risk factors like the following into their own handling process design:

- What kinds of medications they distribute;
- How many receipts and stages there are in the supply chain;
- Written storage instructions from manufacturers;
- Vaccines, insulin, and biological products are examples of medications that are susceptible to freezing or high temperatures.

The importance of GDP in preserving product quality and protecting public health is highlighted by real-world events. As an illustration:

- Temperature-Sensitive Drug Recall: In certain cases, batches of temperature-sensitive drugs were recalled because they were exposed to unsuitable circumstances while being transported. In addition to causing large financial losses, these recalls damage customer trust and may pose health hazards if tainted items are used.
- GDP Implementation Success Stories: Conversely, several pharmaceutical businesses have effectively used cutting-edge GDP-compliant technology, such GPS tracking and real-time temperature monitoring throughout shipping, to guarantee product integrity. In addition to reducing the chance of product deterioration, these actions have improved supply chain accountability and traceability.
- Impact of Comprehensive Training: The focus placed on comprehensive training for employees engaged in pharmaceutical product distribution is another crucial component of GDP. Regular, comprehensive training programs greatly decrease handling mistakes, as demonstrated by well-documented case studies, which helps to ensure the overall quality of pharmaceutical goods.

An outline of the process for GDP certification



Example:

A pharmaceutical business that receives GDP certification from the European Medicines Agency (EMA) is a practical example. The EMA conducted a comprehensive audit of the German-based firm, examining its paperwork, procedures, and facilities to make sure they complied with EU GDP regulations.

Commencing the Certification Procedure:

Each location has a different application procedure for GDP certification. Companies can begin the application procedure in the European Union, for example, by contacting the national responsible authority of the member state in which they are based. To learn more and to start the application procedure, go to the EMA GDP Guidelines website of the European Medicines Agency:

For information and resources on GDP certification, businesses in other areas are advised to consult the websites of the International Society for Pharmaceutical Engineering (ISPE) or the relevant national regulatory body.

Notice of Warning: The Repercussions of Ignoring Appropriate Distribution Techniques
The recipient is the compounding pharmacy ABC Company, which specializes in sterile medication items.

Problem: There was insufficient oversight of the manufacturing environment for pharmaceuticals, which might have resulted in contamination hazards.

Lessons Learned:

- After an inspection at ABC Company, that found serious infractions of the FDA's Current Good Manufacturing Practice (CGMP) rules, which incorporate GDP when it comes to the distribution of sterile items. The USFDA issued a warning notice.
- ABC Company was found to have neglected to maintain the sterility of the areas where sterile goods were made, packaged, and stored. The FDA discovered that spores and microbes were present in crucial locations where sterile items were exposed, according to environmental monitoring.
- The FDA also found that Cantrell failed to take appropriate precautions against product contamination, including inadequate aseptic conduct by employees that might have jeopardized the sterility of its pharmaceutical goods.
- A lack of effective remedial steps and persistent compliance difficulties were highlighted in the warning letter, which also stressed that ABC Company's reaction to the inspection findings was insufficient to address the dangers posed by the environmental pollution identified.

Conclusion

The traceability, accountability, and dependability of the goods that reach consumers are being improved by the implementation of GDP throughout the pharmaceutical and medical device supply chain. However, it's important to keep in mind that the QMS solutions you choose may be tailored to your company's size and the complexity of the activities you must do. The most logical course of action for many distribution organizations is to select a digital QMS that provides the necessary controls along with the flexibility to expand and adapt their strategy as needed.

Useful Links:

1. https://www.cls.co.at/media/files/who_gdp_tr957_annex5_cls_co_at.pdf
2. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/compilation-union-phttps://www.ema.europa.eu/en/human-regulatory/post-authorisation/compliance/good-distribution-practice
3. rocedures-inspections-and-exchange-information_en.pdf
4. https://picscheme.org/docview/3450
5. https://www.ispe.org/
6. https://www.fda.gov/